Ameriprise Financial Inc. Purchases 161,431 Shares of Zoetis Inc. $ZTS

Key Points

• Ameriprise Financial Inc. increased its stake in Zoetis Inc. by 5.0% during the first quarter, bringing its total ownership to approximately 3.4 million shares valued at $556.9 million.
• Zoetis reported strong quarterly earnings, with an EPS of $1.76, surpassing analyst expectations, and a revenue of $2.46 billion, marking a 4.2% increase year-over-year.
• Several analysts have adjusted their ratings for Zoetis, with some lowering target prices while others maintain a "Moderate Buy" consensus rating with an average target price of $202.43.

Ameriprise Financial Inc. increased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,377,184 shares of the company's stock after buying an additional 161,431 shares during the period. Ameriprise Financial Inc. owned about 0.76% of Zoetis worth $556,886,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ZTS. Norinchukin Bank The boosted its holdings in shares of Zoetis by 36.8% during the 1st quarter. Norinchukin Bank The now owns 290,845 shares of the company's stock valued at $47,888,000 after purchasing an additional 78,258 shares during the last quarter. CW Advisors LLC boosted its holdings in shares of Zoetis by 1.3% during the 1st quarter. CW Advisors LLC now owns 85,739 shares of the company's stock valued at $14,113,000 after purchasing an additional 1,104 shares during the last quarter. Wormser Freres Gestion boosted its holdings in shares of Zoetis by 1.9% during the 1st quarter. Wormser Freres Gestion now owns 46,050 shares of the company's stock valued at $7,538,000 after purchasing an additional 843 shares during the last quarter. Sandhill Capital Partners LLC boosted its holdings in shares of Zoetis by 0.6% during the 1st quarter. Sandhill Capital Partners LLC now owns 93,849 shares of the company's stock valued at $15,452,000 after purchasing an additional 600 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Zoetis by 47.1% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 5,778 shares of the company's stock valued at $951,000 after purchasing an additional 1,851 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 0.5%

Shares of NYSE:ZTS traded up $0.7080 during trading on Friday, reaching $156.3180. The company's stock had a trading volume of 2,426,297 shares, compared to its average volume of 3,450,163. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The firm's 50 day simple moving average is $153.84 and its two-hundred day simple moving average is $158.41. The stock has a market capitalization of $69.28 billion, a PE ratio of 26.91, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the firm earned $1.56 EPS. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.